BACKGROUND: Neopterin and tissue polypeptide-specific antigen (TPS) have been suggested to be useful in differential diagnosis between pancreatic adenocarcinoma (PA) and chronic pancreatitis (CP). The aim of our study was to compare the clinical usefulness of CA19-9, neopterin and TPS serum levels in patients with PA and CP. METHODS: The study included 85 patients with PA, 72 with CP and 50 healthy controls. The serum concentrations of neopterin, TPS and CA19-9 were measured (DRG International, USA). The associations of the analyzed markers and clinical data at diagnosis have been evaluated. RESULTS: Serum levels of neopterin, TPS and CA19-9 were higher in PA patients compared to CP (p < 0.001). TPS and CA19-9 levels were also elevated in patients with CP compared to the control group (p < 0.001). In contrast, there was no difference between neopterin serum levels in CP patients and the control group (p > 0.05). Neopterin showed the best sensitivity and specificity (91.8 and 87.5%) in PA diagnosis compared to CA19-9 (respectively 83.5 and 75%) and TPS (75.3 and 65.3%). CONCLUSION: Our results indicate that neopterin may be potentially useful in differential diagnosis between PA and CP. Assessment of TPS probably adds no significant information to that obtained with CA19-9 and neopterin. and IAP.
BACKGROUND:Neopterin and tissue polypeptide-specific antigen (TPS) have been suggested to be useful in differential diagnosis between pancreatic adenocarcinoma (PA) and chronic pancreatitis (CP). The aim of our study was to compare the clinical usefulness of CA19-9, neopterin and TPS serum levels in patients with PA and CP. METHODS: The study included 85 patients with PA, 72 with CP and 50 healthy controls. The serum concentrations of neopterin, TPS and CA19-9 were measured (DRG International, USA). The associations of the analyzed markers and clinical data at diagnosis have been evaluated. RESULTS: Serum levels of neopterin, TPS and CA19-9 were higher in PApatients compared to CP (p < 0.001). TPS and CA19-9 levels were also elevated in patients with CP compared to the control group (p < 0.001). In contrast, there was no difference between neopterin serum levels in CP patients and the control group (p > 0.05). Neopterin showed the best sensitivity and specificity (91.8 and 87.5%) in PA diagnosis compared to CA19-9 (respectively 83.5 and 75%) and TPS (75.3 and 65.3%). CONCLUSION: Our results indicate that neopterin may be potentially useful in differential diagnosis between PA and CP. Assessment of TPS probably adds no significant information to that obtained with CA19-9 and neopterin. and IAP.
Authors: Benjamin F Mann; John A Goetz; Michael G House; C Max Schmidt; Milos V Novotny Journal: Mol Cell Proteomics Date: 2012-03-05 Impact factor: 5.911
Authors: Zobeida Cruz-Monserrate; Kristyn Gumpper; Valentina Pita; Phil A Hart; Christopher Forsmark; David C Whitcomb; Dhiraj Yadav; Richard T Waldron; Stephen Pandol; Hanno Steen; Vincent Anani; Natasha Kanwar; Santhi Swaroop Vege; Savi Appana; Liang Li; Jose Serrano; Jo Ann S Rinaudo; Mark Topazian; Darwin L Conwell Journal: Pancreatology Date: 2021-01-22 Impact factor: 3.996
Authors: Hui Zuo; Grethe S Tell; Stein E Vollset; Per M Ueland; Ottar Nygård; Øivind Midttun; Klaus Meyer; Arve Ulvik; Simone J P M Eussen Journal: Cancer Date: 2014-06-19 Impact factor: 6.860